BioVinc, Pasadena, CA, USA.
Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Br J Pharmacol. 2021 May;178(9):2008-2025. doi: 10.1111/bph.15251. Epub 2021 Apr 10.
Advances in the design of potential bone-selective drugs for the treatment of various bone-related diseases are creating exciting new directions for multiple unmet medical needs. For bone-related cancers, off-target/non-bone toxicities with current drugs represent a significant barrier to the quality of life of affected patients. For bone infections and osteomyelitis, bacterial biofilms on infected bones limit the efficacy of antibiotics because it is hard to access the bacteria with current approaches. Promising new experimental approaches to therapy, based on bone-targeting of drugs, have been used in animal models of these conditions and demonstrate improved efficacy and safety. The success of these drug-design strategies bodes well for the development of therapies with improved efficacy for the treatment of diseases affecting the skeleton. LINKED ARTICLES: This article is part of a themed issue on The molecular pharmacology of bone and cancer-related bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.
在设计用于治疗各种与骨骼相关疾病的潜在骨选择性药物方面的进展，为多种未满足的医疗需求开辟了令人兴奋的新方向。对于与骨骼相关的癌症，目前药物的脱靶/非骨骼毒性是影响患者生活质量的一个重大障碍。对于骨骼感染和骨髓炎，受感染骨骼上的细菌生物膜限制了抗生素的疗效，因为目前的方法很难接触到细菌。基于药物靶向骨骼的有前途的新实验治疗方法已在这些疾病的动物模型中得到应用，并证明了疗效和安全性的提高。这些药物设计策略的成功为开发治疗骨骼疾病的疗效更好的疗法提供了良好的前景。相关文章：本文是关于骨骼和与癌症相关的骨骼疾病的分子药理学的专题的一部分。要查看本节中的其他文章，请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc.
